Revenue - Additional Information (Detail) - USD ($)	3 Months Ended			12 Months Ended
	Dec. 31, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Disaggregation Of Revenue [Line Items]
Revenue		$ 11,684,000	$ 7,683,000
Accounts and other receivables, net		3,015,000				$ 805,000
Current liabilities		62,580,000				63,263,000
Accrued expenses		15,940,000				17,521,000
Accounts payable		$ 7,082,000				6,504,000
Alimera Sciences, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Product rights agreement, closing date		May 17, 2023
Receipt of upfront license fee		$ 75,000,000
RPA [Member] | SWK [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment		16,500,000
Revenue		300,000	300,000
Deferred revenue, current		1,400,000				1,400,000
Deferred revenue, non-current		12,100,000				$ 12,400,000
YUTIQ [Member]
Disaggregation Of Revenue [Line Items]
Revenue		700,000	7,400,000
Product [Member]
Disaggregation Of Revenue [Line Items]
Revenue		658,000	7,394,000
Product [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue		0
Product [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue		700,000
License and Collaboration Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue		10,563,000	34,000
Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Revenue		463,000	$ 255,000
Royalty Income [Member] | Ocumension Therapeutics [Member]
Disaggregation Of Revenue [Line Items]
Revenue		200,000
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Upfront cash payment		75,000,000
Deferred revenue, current		37,000,000
Deferred revenue, non-current		$ 37,000,000
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Scenario, Forecast [Member]
Disaggregation Of Revenue [Line Items]
Guaranteed payments	$ 1,875,000				$ 7,500,000
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Maximum [Member]
Disaggregation Of Revenue [Line Items]
Royalties payment period		2028
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Maximum [Member] | Scenario, Forecast [Member]
Disaggregation Of Revenue [Line Items]
Royalty payments				$ 70,000,000
Product Rights Agreement [Member] | Alimera Sciences, Inc. [Member] | Minimum [Member]
Disaggregation Of Revenue [Line Items]
Royalties payment period		2025
Product Rights Agreement [Member] | Product Rights Agreement and the Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Revenue		$ 10,400,000
Commercial Supply Agreement [Member] | Alimera Sciences, Inc. [Member]
Disaggregation Of Revenue [Line Items]
Initial term of the supply agreement		2 years
Initial Term of Estimated Supply Units		2 years